Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial

K. Litton, Jennifer; A. Hurvitz, Sara; A. Mina, Lida; S. Rugo, Hope; Hoon Lee, Ki; Gonçalvès, Anthony; Diab, Sami; Woodward, Natasha; Goodwin, Annabel; Yerushalmi, Rinat; Roché, Henri; Im, Young‐Hyuck; Eiermann, W.; G.W. Quek, Ruben; Usari, Tiziana; Lanzalone, Silvana; Czibere, Akos; L. Blum, Joanne; Martín, Miguel; Ettl, Johannes

doi:10.1016/j.annonc.2020.08.2098

Public

Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial

Published in Annals of Oncology • Aug 20, 2020

Authors:

Jennifer K. Litton

Sara A. Hurvitz

Lida A. Mina

Abstract

BACKGROUND: In EMBRACA, talazoparib prolonged progression-free survival versus chemotherapy (hazard ratio [HR] 0.542 [95% confidence interval (CI) 0.413-0.711]; P < 0.0001) and improved patient-reported outcomes (PRO) in germline BRCA1/2 (gBRCA1/2)-mutated advanced breast cancer (ABC). We report fin...

Subject

Medicine

Hazard ratio

Chemotherapy

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!